He and his colleagues are now working on developing an even more sensitive and more comprehensive second-generation assay, which, he says, should overcome one of the current limitations of the ctHPVDNA assay used in the study in which ctHPVDNA eludes detection in some patients. “For example, in our study, one out of 70 patients did not have ctHPVDNA detectable using our assay (sensitivity of 98.4%),” he said. “However, we believe this is a limitation of the technology platform that can be overcome with approaches we are now working on.”
Blood-Based Diagnosis of Head and Neck Cancer
by Mary Beth Nierengarten •
You Might Also Like:
- Increased Antibiotic Prescribing Period Associated with Delayed Head and Neck Cancer Diagnosis
- Head and Neck Cancer: What Can Be Done to Mitigate Differences in Diagnosis Between Healthcare Providers?
- Probe-Based Confocal Laser Endomicroscopy Effective in Detecting Head and Neck Cancers
- Is it Safe to Kiss in Era of HPV Head and Neck Cancer ‘Epidemic’?